Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsColorado Rocky Mountain Otarmeni Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentColorado Rocky Mountain Health PlansPolicy 2026D0143A

    Otarmeni (Lunsotogene Parvec-Cwha) Coverage Criteria

    Customize your policy alerts

    Sign up for Colorado Rocky Mountain Health Plans Policy 2026D0143A alerts

    Get alerted when Policy 2026D0143A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization for Otarmeni gene therapy in pediatric and adult patients with qualifying OTOF-related severe-to-profound or profound sensorineural hearing loss.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyOtarmeni (Lunsotogene Parvec-Cwha) Coverage Criteria
    Policy CodePolicy 2026D0143A
    Change TypeNew policy
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and submit documentation supporting all clinical criteria before billing Otarmeni.
    SourceLink
    POLICY UPDATE CHANGES

    A new medical benefit drug policy was added establishing coverage criteria for Otarmeni.

    >90 dB HLQualifying hearing-loss threshold
    Biallelic OTOFRequired genetic finding
    1 treatment/earLifetime limit
    60 daysAuthorization duration
    24

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Clinical study participants
    10/12Study patients achieving PTA ≤70 dB HL

    Otarmeni Coverage Criteria

    Initial Otarmeni Coverage

    Otarmeni is proven for the treatment of pediatric and adult patients with sensorineural hearing loss when all of the following criteria are met:

    Initial coverage criteria

    • Clinical eligibility: Patient has severe-to-profound or profound sensorineural hearing loss defined as any frequency >90 dB HL.>90 dB HL
    • Genetic confirmation: Patient has molecularly confirmed biallelic variants in the OTOF gene.Biallelic OTOF variants
    • Cochlear function: Patient has preserved outer hair cell function.
    • Prior implant status: The ear to be treated has not previously received a cochlear implant.No prior cochlear implant in same ear
    • Anatomic feasibility: Preoperative imaging demonstrates that access to the inner ear is feasible, with no abnormal mastoid pneumatization or clinically significant anatomic variations of the middle ear or inner ear.
    • Dosing is in accordance with FDA-approved labeling.FDA-labeled dosing
    • Authorization limits: Authorization is issued for no more than one treatment per ear per lifetime and for no longer than 60 days from approval.1 treatment/ear/lifetime; ≤60 days

    Otarmeni is not recommended when preoperative imaging demonstrates that access to the inner ear is not feasible. This includes abnormal mastoid pneumatization or clinically significant anatomic variations of the middle ear or inner ear.

    Coverage requires that the requested ear has no prior cochlear implant. Otarmeni is not recommended when the ear to be treated has previously received a cochlear implant.

    Coding and Authorization Parameters

    Applicable Drug CodesHCPCS
    C9399Unclassified drugs or biologicals
    J3590Unclassified biologics
    Applicable Diagnosis CodesICD-10
    H90.3Sensorineural hearing loss, bilateral
    H90.41Sensorineural hearing loss, unilateral, right ear, with unrestricted hearing on the contralateral side
    H90.42Sensorineural hearing loss, unilateral, left ear, with unrestricted hearing on the contralateral side
    H90.5Unspecified sensorineural hearing loss
    H90.A21Sensorineural hearing loss, unilateral, right ear, with restricted hearing on the contralateral side
    H90.A22Sensorineural hearing loss, unilateral, left ear, with restricted hearing on the contralateral side
    Qualifying hearing loss
    ThresholdAny frequency greater than 90 dB HL
    ConditionSevere-to-profound or profound sensorineural hearing loss
    Applies toPediatric and adult patients
    Authorization duration
    Maximum durationNo longer than 60 days from approval
    Authorization basisOtarmeni coverage authorization
    Duration begins

    Provider Submission Requirements

    Prior Authorization

    Prior Authorization Required

    Submit prior authorization for Otarmeni (lunsotogene parvec-cwha) before treatment. Include the requested ear, clinical eligibility documentation, treatment plan, and FDA-label-concordant dosing information.

    Documentation Required

    Hearing Loss and Genetic Documentation

    Document the hearing-loss diagnosis and the molecular basis for treatment. Coverage requires severe-to-profound or profound sensorineural hearing loss, defined as any frequency greater than 90 dB HL, with molecularly confirmed biallelic OTOF variants and preserved outer hair cell function.

    • Audiologic documentation showing hearing loss at any frequency > 90 dB HL.
    • Molecular test results confirming biallelic OTOF variants.
    • Documentation of preserved outer hair cell function.

    Therapy Background

    Otarmeni (lunsotogene parvec-cwha) is a dual adeno-associated virus gene therapy that delivers a functional copy of the OTOF gene to cochlear hair cells, enabling synaptic transmission between inner hair cells and the cochlear nerve. It is administered as a single intracochlear infusion under general anesthesia using a surgical approach similar to cochlear implantation. Biallelic pathogenic OTOF variants cause a subset of congenital genetic deafness.

    Clinical Definitions

    Severe-to-profound or profound sensorineural hearing loss
    DefinitionSensorineural hearing loss with any frequency greater than 90 dB HL
    ClassificationSevere-to-profound or profound sensorineural hearing loss
    Hearing-level unitdB HL (decibel hearing level)
    Molecularly confirmed biallelic OTOF variants
    Genetic findingMolecularly confirmed biallelic variants in the OTOF gene
    Variant distributionPathogenic variants are present on both alleles
    Gene product

    Initial Therapy Eligibility

    Initial Otarmeni Therapy

    Initial treatment is covered when all of the following criteria are met:

    Otarmeni initial therapy: Patient meets the policy's hearing-loss, genetic, outer-hair-cell, prior-implant, imaging, and FDA-label dosing criteria; authorization is limited to one treatment per ear per lifetime and 60 days from approval.

    Treatment and Authorization Limits

    Otarmeni lifetime treatment limit
    DrugOtarmeni
    Maximum treatmentNo more than one treatment per ear per lifetime
    Limit applies perEar
    Otarmeni authorization duration
    DrugOtarmeni
    Maximum authorization durationNo longer than 60 days from approval
    Duration beginsFrom approval
    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyOtarmeni (Lunsotogene Parvec-Cwha) Coverage Criteria
    Policy CodePolicy 2026D0143A
    Change TypeNew policy
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and submit documentation supporting all clinical criteria before billing Otarmeni.
    SourceLink
    On This Page
    Otarmeni Coverage CriteriaCoding and Authorization ParametersProvider Submission RequirementsTherapy BackgroundClinical DefinitionsInitial Therapy EligibilityTreatment and Authorization Limits
    From approval
    Lifetime treatment limit
    Maximum treatment frequencyNo more than one treatment per ear per lifetime
    Limit applies perEar
    Lifetime limitOne treatment per ear
    Documentation Required

    Preoperative Imaging Required

    Provide preoperative imaging documentation showing that access to the inner ear is feasible. Imaging should address the absence of abnormal mastoid pneumatization and clinically significant anatomic variations of the middle or inner ear.

    • Include the relevant preoperative imaging report and anatomic findings.
    • Otarmeni is not recommended when inner-ear access is not feasible.

    Unsupported block type: documentation

    Denial Risk

    Missing Eligibility Criteria May Result in Denial

    Requests may be denied when the required clinical eligibility criteria are missing or cannot be verified. Ensure the submission addresses hearing-loss severity, biallelic OTOF molecular confirmation, preserved outer hair cell function, feasible inner-ear access, and all other applicable eligibility requirements.

    • Severe-to-profound or profound sensorineural hearing loss: any frequency > 90 dB HL.
    • Molecularly confirmed biallelic OTOF variants.
    • Preserved outer hair cell function.
    • Preoperative imaging demonstrating feasible inner-ear access.
    Denial Risk

    Prior Implant or Nonconforming Dosing

    Coverage may be denied if the requested ear has a prior cochlear implant or if the proposed dosing does not conform to FDA-approved labeling. Verify these conditions before submitting the authorization.

    • No prior cochlear implant in the same ear.
    • Dosing must follow FDA-approved labeling.
    Denial Risk

    Lifetime and Authorization-Duration Limits

    Authorization is limited to no more than one Otarmeni treatment per ear per lifetime and no longer than 60 days from approval. Requests exceeding either limit may be denied or limited.

    • Maximum: one treatment per ear per lifetime.
    • Maximum authorization duration: 60 days from approval.
    The OTOF gene encodes otoferlin
    Preserved outer hair cell function
    DefinitionFunctional activity of cochlear outer hair cells
    Testing methodOtoacoustic emissions testing
    Required findingEvidence of outer hair cell activity